Please ensure Javascript is enabled for purposes of website accessibility

Inovio Ramps Up Production of Its Coronavirus Vaccine Candidate

By Brian Orelli, PhD - Apr 30, 2020 at 3:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech is moving quickly, but has a lot of potential competition.

Inovio Pharmaceuticals' (INO 9.25%) SARS-CoV-2 vaccine candidate, INO-4800, is only in phase 1 development, but the biotech is already preparing to produce it at scale through a partnership with the German contract manufacturer Richter-Helm BioLogics.

The biotech has been working with Richter-Helm BioLogics since 2014 to manufacture its human papillomavirus vaccine, VGX-3100, which was developed using the same DNA medicine platform as INO-4800. The coronavirus vaccine being tested in the phase 1 clinical trial was manufactured by VGXI, but Richter-Helm BioLogics uses the same technology (which VGXI developed). Many drugs have been manufactured first at VGXI, and then transferred to Richter-Helm when the time came to produce them in commercial quantities, so the technology transfer and scale-up should be fairly routine.

Financial terms of the deal weren't disclosed, but the Coalition for Epidemic Preparedness Innovations (CEPI) is chipping in $1.3 million through a grant to Inovio to help ramp up production. CEPI has been supporting the development of INO-4800 since January, contributing a total of $17.2 million to the project including the recent manufacturing grant.

Gloved hands giving an injection into a shoulder

Image source: Getty Images.

Inovio hopes to advance INO-4800 into a combined phase 2/3 clinical trial this summer. The company plans to have 1 million doses of the potential coronavirus vaccine available by the end of 2020.

While it's great to see Inovio working at a rapid pace to develop a vaccine to prevent COVID-19, investors should keep in mind that the company has lots of competition -- around 70 candidate vaccines are in development for the novel coronavirus. Moderna's (MRNA 4.97%) candidate, mRNA-1273, is further along -- it's ready to go into a phase 2 clinical trial as soon as the Food and Drug Administration signs off.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.89 (9.25%) $0.16
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$149.95 (4.97%) $7.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.